Second Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors After PCV-Chemotherapy
OBJECTIVES: I. Determine the response rate and duration of response in oligodendroglial
tumors to temozolomide treatment in patients with progressive disease during or after
procarbazine/lomustine/vincristine (PCV) chemotherapy. II. Determine the feasibility and
toxicity of temozolomide chemotherapy following PVC chemotherapy in these patients.
OUTLINE: This is an open label, multicenter trial. Temozolomide is administered orally on
days 1-5 of each 4-week course; treatment continues for a maximum of 12 courses. Patients
are followed every 2 months for the first 6 months and then every 3 months thereafter.
PROJECTED ACCRUAL: A total of 16-29 patients will be accrued for this study.
Primary Purpose: Treatment
Martin J. van Den Bent, MD
Daniel Den Hoed Cancer Center at Erasmus Medical Center
United States: Federal Government